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Abstract
Summary In an open-label extension study, BMD increased
continuously with strontium ranelate over 10 years in osteopo-
rotic women (P<0.01). Vertebral and nonvertebral fracture
incidence was lower between 5 and 10 years than in a matched
placebo group over 5 years (P<0.05). Strontium ranelate's
antifracture efficacy appears to be maintained long term.
Introduction Strontium ranelate has proven efficacy against
vertebral and nonvertebral fractures, including hip, over
5 years in postmenopausal osteoporosis. We explored long-
term efficacy and safety of strontium ranelate over 10 years.
Methods Postmenopausal osteoporotic women participating
in the double-blind, placebo-controlled phase 3 studies
SOTI and TROPOS to 5 years were invited to enter a 5-
year open-label extension, during which they received
strontium ranelate 2 g/day (n=237, 10-year population).
Bone mineral density (BMD) and fracture incidence were
recorded, and FRAX® scores were calculated. The effect of
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strontium ranelate on fracture incidence was evaluated by
comparison with a FRAX®-matched placebo group identi-
fied in the TROPOS placebo arm.
Results The patients in the 10-year population had baseline
characteristics comparable to those of the total SOTI/
TROPOS population. Over 10 years, lumbar BMD
increased continuously and significantly (P<0.01 versus
previous year) with 34.5±20.2% relative change from
baseline to 10 years. The incidence of vertebral and
nonvertebral fracture with strontium ranelate in the 10-
year population in years 6 to 10 was comparable to the
incidence between years 0 and 5, but was significantly
lower than the incidence observed in the FRAX®-matched
placebo group over 5 years (P<0.05); relative risk
reductions for vertebral and nonvertebral fractures were
35% and 38%, respectively. Strontium ranelate was safe
and well tolerated over 10 years.
Conclusions Long-term treatment with strontium ranelate is
associated with sustained increases in BMD over 10 years,
with a good safety profile. Our results also support the
maintenance of antifracture efficacy over 10 years with
strontium ranelate.
Keywords BMD . Long-term treatment . Osteoporotic
fracture . Strontium ranelate
Introduction
Osteoporosis is a chronic disease requiring chronic treat-
ment. It is therefore essential to evaluate the efficacy and
safety of osteoporosis treatments for the longest time
possible, i.e. well beyond the 3 to 5 years recommended
by the regulatory authorities. Thus, clinical studies for the
bisphosphonates zoledronic acid, risedronate, and alendro-
nate have been extended to 6, 7, and 10 years, respectively
[1–3]; the selective estrogen receptor modulator raloxifene
has been evaluated up to 8 years [4, 5]; and results at 5 to
6 years are available for the human monoclonal antibody
denosumab [6, 7]. These studies generally indicate sus-
tained increases in the surrogate marker of antifracture
efficacy, bone mineral density (BMD). The study designs,
notably excluding a placebo group for ethical reasons,
preclude direct measurement of long-term reductions in
fracture incidence.
The orally active agent strontium ranelate is indicated for
the management of postmenopausal osteoporosis. Its mode of
action in osteoporotic bone includes opposite effects on
resorption and formation, which is associated with an
improvement in the material or structural properties of bone
[8]. Two international, double-blind, placebo-controlled
phase 3 studies in postmenopausal women with osteoporosis,
the Spinal Osteoporosis Therapeutic Intervention (SOTI) and
Treatment of Peripheral Osteoporosis (TROPOS) trials,
demonstrated the efficacy of strontium ranelate in reducing
the risk of vertebral, nonvertebral, and hip fracture in a
subgroup of patients at high risk [9, 10]. This efficacy was
found to be independent of baseline risk factors [11] and to
be maintained over 5 years against placebo [12] with a good
safety profile. Results of a pooled extension study of the
SOTI and TROPOS populations to 8 years [13] suggested
the maintenance of the antifracture efficacy over 8 years of
continuous treatment with strontium ranelate. In this article,
we describe the results of a pooled longer-term open-label
extension of the SOTI and TROPOS studies to evaluate the
efficacy and safety of strontium ranelate up to 10 years.
Methods
Study design and patients
The procedures for the open-label extension study of SOTI
and TROPOS have been described extensively elsewhere
[13]. The initial 3-year extension (8 years’ continuous
treatment) was increased by 2 years to reach a total of
10 years’ continuous follow-up. The 10-year extension
study therefore enrolled postmenopausal women with
osteoporosis who had completed 5 years of treatment with
strontium ranelate or placebo in the SOTI and TROPOS
studies (years 0 to 5) plus a further 5 years of treatment in
the extension phase (years 6 to 10) [9, 10] (Fig. 1). The
main reasons for not continuing were either patient’s own
personal decision or investigator’s decision according to the
patient’s status (e.g. age or mobility). During the open-label
extension, all patients received strontium ranelate 2 g/day,
as well as calcium (< 1000 mg/day) and vitamin D (400 to
800 IU/day). All patients gave written informed consent
before inclusion in both parts of the extension study (at year
6 and year 9), which was approved by institutional ethics
review committees. In this article, results will be restricted
to the 10-year population (n=237), i.e. patients from the
active treatment arms of SOTI and TROPOS who received
strontium ranelate for up to 10 years.
Efficacy endpoints
The main efficacy endpoints were the incidence of new
osteoporotic fractures and the change in lumbar spine,
femoral neck, and total hip BMD between years 6 and 10.
The procedures used to evaluate the incidence of fractures
are described in detail in the original reports [9, 10, 13]. All
patients from the SOTI trial had spinal X-rays at inclusion
and yearly thereafter. The patients from the TROPOS study
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in whom spinal X-rays were routinely performed continued
to have them in the extension phase. Spinal X-rays were
read centrally and incident vertebral fracture detected by
semi-quantitative assessment and grading [14]. Clinical
peripheral (nonvertebral) osteoporosis-related fractures
were assessed in all patients according to radiological
evaluation and written documentation (radiological, hospitali-
zation, or emergency room report). All peripheral fractures
(including hip) were considered as osteoporosis-related, except
when they concerned the skull, face or jaw, coccyx, phalanx
(fingers or toes), or ankle. New fracture was defined as the
occurrence of a new vertebral, nonvertebral, or hip fracture in
years 6 to 10, independently of any fracture incurred in years 0
to 5 (which were considered as previous fractures for the
purposes of the extension study).
BMD was measured by dual energy X-ray absorptiom-
etry (DXA, Hologic) at entry to the extension study (year 6)
and yearly thereafter, using the same acquisition program
and quality control as the original studies [9, 10, 15].
FRAX® [16, 17] was used to evaluate individual
patients’ risk of fracture in the 10-year population at 5 years.
The FRAX® algorithm integrates a number of clinical risk
factors, including BMD at the femoral neck, to give a 10-
year probability of hip or major osteoporotic fracture
(clinical vertebral, forearm, hip, or shoulder fracture). In
this study, FRAX was calculated without BMD in patients
previously treated with strontium ranelate for 5 years.
Safety and compliance
Blood and urine chemistry, hematology, and blood stron-
tium were assessed every 12 months. Adverse events were
collected at each 6-month visit. Patient compliance was
assessed by the number of unused sachets returned every
6 months.
Statistical methods
The baseline characteristics of the 10-year population at
year 0 are presented as mean±SD for continuous variables
and number of patients (%) for categorical variables. The
analysis was performed in the full analysis set (FAS)
comprising all patients who had at least one intake of
strontium ranelate after inclusion at year 9, at least one
measurement of lumbar spine L2–L4 BMD at baseline
(year 9) and between years 9 and 10, and at least one
evaluation of fracture between years 9 and 10. Cumulative
incidence of new vertebral, nonvertebral, or any osteopo-
rotic fracture was estimated by the Kaplan–Meier method in
the first 5 years (years 0 to 5) and in the 5 years of the
extension study (years 6 to 10). McNemar’s test was used
to compare the number of patients experiencing at least one
fracture during the first 5 years in the 10-year population
with that of patients experiencing at least one new fracture
during the 5 years of the extension study. Change in BMD
Fig. 1 Flow of patients
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and relative change from baseline to each visit were
calculated and compared within the group (previous year)
using a Student t test for paired samples.
To assess the long-term antifracture efficacy of strontium
ranelate in the absence of a placebo group, we sought a
matching population in the placebo group of TROPOS
(years 0 to 5). In this post-hoc exploratory analysis, 10-year
fracture probabilities for major osteoporotic fracture in the
10-year population and in the FRAX®-matched placebo
population were calculated as mean values of the individual
FRAX® probabilities. To ensure the comparability of the
two populations, we identified patients in the placebo group
with the same FRAX® score, i.e. 10-year probability of
major osteoporotic fracture, at baseline (year 0) as the 10-
year population at entry to the extension study (year 6)
using a modified case–control analysis with a ratio of two
patients from TROPOS to one patient from the extension
study. This FRAX®-matched placebo population comprised
458 patients. The Greedy’s algorithm (an optimal version of
the k-means method) with six clusters was used.
A P value of 0.05 or less was considered significant.
Statistical analysis was performed using SAS/PC software
version 9.1.
Results
Patient characteristics
The 10-year extension study was performed in 36 centers in
eight European countries and Australia. Out of the 2055
patients who entered the extension study at 5 years, 1420
(69%) completed the 3-year treatment period to 8 years. A
total of 603 patients accepted to participate in the 2-year
prolongation of the extension study to 10 years, of whom 237
had been treated with strontium ranelate for 8 years (i.e. the
10-year population, Fig. 1). The 10-year population consisted
of 233 patients (56 from SOTI and 177 from TROPOS; four
patients excluded since they did not take the study
treatment). The characteristics of the 10-year population at
year 0 were similar to those of the two main study
populations at year 0 (Table 1).
The mean persistence with strontium ranelate in the 10-
year population was 117.8±6.1 months (i.e. 9 years and
9 months); the mean compliance was 89.4±12.6%. Blood
strontium values reached a plateau after 3 months of
treatment. Mean values of blood strontium ranged from
136.1±89.3 to 158.8±105.7 μmol/L and were consistent
with good exposure to the treatment over 10 years.
Fractures
The cumulative incidence of new fracture in the 10-year
population in years 6 to 10 was similar to the cumulative
incidence in years 0 to 5 (vertebral fracture: 20.6±3.0%
versus 18.5±2.6%, respectively, P=1.00; non-vertebral
fracture: 13.7±2.3% versus 12.9±2.2%, P=0.672; and any
osteoporotic fracture: 30.3±3.1% versus 27.5±2.9%, P=
0.734) (Fig. 2). The 10-year population had a mean
FRAX® 10-year probability of major osteoporotic fracture
(calculated without BMD) of 25.8±9.6% at the time of their
inclusion in the extension study (at year 6).
The effect of strontium ranelate on fracture incidence
was evaluated by comparison with a FRAX®-matched
placebo group identified in the TROPOS placebo arm. The
FRAX®-matched placebo population of TROPOS had a
mean FRAX® 10-year probability of major osteoporotic
fracture of 25.8±9.3% at the baseline (year 0). The patients
in these two populations were similar in terms of age, BMI,
time since menopause, parental history of osteoporotic
fracture, and prevalence of osteoporotic fracture (Table 2).
The cumulative incidences of fracture in the 10-year
population were compared with the cumulative incidence
of fracture in the FRAX®-matched placebo population
Table 1 Baseline characteristics
at year 0
BMD bone mineral density
aRandomized set SOTI and
TROPOS excluding the 10-year
population
Pooled SOTI and
TROPOSa (n=6503)
10-Year population
(n=237)
Age (years) 75.2±6.4 72.0±5.4
Body mass index (kg/m2) 25.65±4.09 25.80±3.82
Time since menopause (years) 27.4±8.3 23.65±6.81
≥ 1 Prevalent nonvertebral fracture, n (%) 2365 (36) 103 (44)
≥ 1 Prevalent vertebral fracture, n (%) 2857 (44) 100 (45)
Lumbar BMD (g/cm2) 0.781±0.152 0.755±0.136
T-score −3.00±1.52 −3.266±1.420
Femoral neck BMD (g/cm2) 0.561±0.075 0.576±0.063
T-score −3.06±0.67 −2.946±0.566
Total hip BMD (g/cm2) 0.658±0.102 0.688±0.089
T-score −2.64±1.00 −2.344±0.876
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(Fig. 2). The cumulative incidence of new vertebral
fractures in the 10-year population in years 6 to 10 was
significantly lower than that observed over 5 years in the
FRAX®-matched placebo population (20.6±3.0% versus
28.2±2.4%, respectively; relative reduction in risk [RRR]
35%, P=0.016). Similarly, the 10-year population had
significantly lower rates of nonvertebral fracture and new
osteoporotic fracture in years 6 to 10 than the FRAX®-
matched placebo population over 5 years (nonvertebral
fracture: 13.7±2.3% versus 20.2±2.2%, respectively, RRR
38%, P=0.023; new osteoporotic fracture: 30.3±3.1%
versus 39.2±2.5%, RRR 30%, P=0.012).
Bone mineral density
Over the 10-year period, lumbar BMD increased continuously
with a mean relative change from baseline of 34.5±20.2%
(Table 3) in the 10-year population treated with strontium
ranelate. At this site, the annual change remained significant
over the whole 10-year period (P<0.001 up to year 9 and P=
0.002 for the last year). After 10 years’ treatment with
strontium ranelate, the mean relative changes in BMD from
baseline were 10.7±12.1% at the femoral neck and 11.7±
13.6% for total hip. At both sites, the BMD increased
significantly until year 7 and remained stable thereafter.
Correlation between changes in BMD and incidence
of fracture
Our analysis included 116 women with femoral neck and
total hip BMD and fracture data available over the 10 years
of follow-up. During the last 2 years of follow-up, 12 of
these patients experienced a new vertebral fracture. After
having controlled for age, body mass index at year 9, BMD
at year 9, number of vertebral fractures at year 0, and
number of new vertebral fractures from years 0 to 8, we
found that the change in femoral neck BMD from years 9 to
10 was significantly associated with vertebral fractures
incidence during the same period of time (P=0.03). Each
1% increase in femoral neck BMD was associated with a
15% (95% adjusted confidence interval [CI] 2–26%)
decrease in risk for new vertebral fracture. The same trend
Fig. 2 Cumulative incidence of new vertebral fracture (A), new
nonvertebral fracture (B), and new osteoporotic fracture (C) in the 10-
year population between 0 and 5 years’ treatment with strontium
ranelate and between 6 and 10 years’ treatment with strontium ranelate
(gray bars) and in the FRAX®-matched placebo group of TROPOS
between 0 and 5 years (white bars)
Table 2 Main characteristics of
the FRAX®-matched groups at
year 0, in comparison with the
characteristics of the 10-year
population at 5 years
10-Year population
at 5 years (n=233)
TROPOS FRAX®-matched
placebo group at year 0 (n=458)
FRAX score (%) 25.8±9.6 25.8±9.3
Age (years) 77.3±5.3 76.3±4.7
Body mass index (kg/m2) 25.8±4.1 25.2±3.7
Time since menopause (years) 28.4±6.8 28.4±7.4
Parental history of osteoporotic fracture, n (%) 92 (39) 146 (32)
≥ 1 Prevalent osteoporotic fracture, n (%) 177 (76) 309 (67)
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was observed for total hip BMD (7%; 95% CI 3–17%), but
did not reach statistical significance (P=0.16). Women with
new vertebral fractures from years 9 to 10 experienced a
simultaneous decrease of 2.4±4.7% in femoral neck BMD,
compared with an increase of 1.5±8.3% in women without
new vertebral fracture.
Safety
During the extension study, 226 patients (95%) in the 10-
year population reported at least one emergent adverse
event on treatment. The comparison of the incidences of the
most frequent adverse events observed with strontium
ranelate in the 5 years of the SOTI and TROPOS studies
and those in years 6 to 10 (Table 4) shows no increase after
long-term use in an aging population. The annual incidence
of events related to venous thromboembolism in patients
treated with strontium ranelate during the 5 years of the
extension study (i.e. patients who had received treatment for
10 years) was 0.4%. The neurological disorders reported
included memory losses (annual incidence 1.1%) and dis-
turbances in consciousness (annual incidence 0.8%), but no
case of seizure. Moreover, no new signal was detected over
the last 2 years of the extension study; no cases of drug-related
hypersensitivity reactions were reported in the extension
study.
Discussion
Our results indicate a stable fracture rate and maintenance
of BMD with strontium ranelate treatment over 10 years,
despite an increase in age and prevalent fractures in the
population. The major result of our study is the comparable
cumulative incidences of vertebral and nonvertebral frac-
ture in the same population over two consecutive 5-year
periods. The significantly lower rate of fracture than the
FRAX®-matched placebo group could be considered as
indirect evidence for the sustained antifracture efficacy of
strontium ranelate over 10 years of treatment. Our findings
also support the safety of strontium ranelate up to 10 years'
treatment, with rates of events related to venous thrombo-
embolism and neurological disorders in accordance with
those observed over 5 years in the original studies.
Table 3 Change in bone
mineral density (BMD) in
patients treated with strontium
ranelate for 10 years
*P<0.05; **P<0.01;
***P<0.001, for within-group
comparison
No. of patients Mean change (g/cm2) Mean relative change
from baseline (%)
Lumbar spine L2-L4
Baseline to year 10 155 0.253±0.151*** 34.5±20.2***
Years 0–5 223 0.179±0.105*** 23.9±13.9***
Years 6-10 146 0.070±0.115** 7.9±12.6**
Femoral neck
Baseline to year 10 147 0.060±0.066*** 10.7±12.1***
Years 0–5 225 0.050±0.044*** 8.8±8.0***
Years 6–10 130 0.010±0.056* 1.8±9.1*
Total hip
Baseline to year 10 147 0.077±0.084*** 11.7±13.6***
Years 0–5 225 0.080±0.056*** 12.1±11.2***
Years 6–10 130 0.000±0.067 0.04±8.9
Table 4 Adverse events
reported during the extension
study compared with those
reported in the 5 years of the
SOTI and TROPOS trials in
patients receiving strontium
ranelate
Pooled SOTI–TROPOS strontium
ranelate group (n=3352)
10-Year population (n=237)
0–5 years 6–10 years
Nervous system disorder
Headache 112 (3.3%) 3 (1.3%)
Gastrointestinal disorder
Nausea 239 (7.1%) 2 (0.8%)
Diarrhea 234 (7.0%) 11 (4.6%)
Skin and subcutaneous tissue disorder
Dermatitis 76 (2.3%) 0 (0.0%)
Eczema 59 (1.8%) 3 (1.3%)
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Long-term trials are not simple to perform, and exten-
sion studies are fraught with methodological problems
associated with an open-label design, small samples, and
the absence of a placebo control. In osteoporosis, this
renders antifracture efficacy difficult to evaluate, decreasing
the reliability of the results [18]. Long-term treatment with
alendronate has been explored in an extension study, in
which patients who had received 5 years’ treatment entered
a 5-year extension with alendronate or placebo [2]. The
objective was to assess the effects of continuation or
discontinuation of alendronate on BMD after 5 years’
treatment, while the incidence of fracture constituted an
exploratory endpoint only. There was a continuous increase
in BMD at the lumbar spine with long-term alendronate,
and plateaus at the other sites. Despite the small but
statistically significant between-group differences in BMD,
there was no increase in morphometric vertebral or non-
vertebral fractures among patients who discontinued versus
those who continued alendronate. However, there was a
2.9% significant absolute risk increase in clinical spine
fracture in patients who discontinued treatment. Another
alendronate study [19] showed similar effects on BMD after
10 years’ treatment, but again could not conclude on
vertebral fracture incidence, which was assessed as a safety
rather than efficacy endpoint. Similar results were reported
for risedronate in a study in which 83 patients continued for
7 years [1].
Another agent that has been tested long term is
raloxifene, for which results over 8 years in women with
breast cancer showed maintenance of the increases in
lumbar spine and femoral neck BMD, but was inconclusive
on fracture risk [4, 5]. Results for denosumab indicate
continuous increases in BMD over 5 to 6 years at all sites
with incidences of vertebral and nonvertebral fracture
below rates observed in the phase 3 placebo group [6, 7].
The main reason for the difficulties in demonstrating an
impact on fracture incidence in these long-term studies is
the absence of a placebo control. One solution is to
compare fracture incidence with the first years of the study,
in which efficacy versus placebo has already been demon-
strated. Thus, the 8-year pooled analysis of SOTI and
TROPOS reported no statistical difference between incidence
of fracture in the first 3 years of the trials (years 0 to 3) and the
first 3 years of the extension (years 6 to 8) for vertebral,
nonvertebral, or any osteoporotic fracture [13]. Our finding of
similar rates in the first 5 years (years 0 to 5) and the last
5 years (years 6 to 10) reinforces the conclusion that the
antifracture efficacy of strontium ranelate is sustained in the
long-term. However, we also compared these cumulative
incidences with those in a FRAX®-matched placebo
population in the TROPOS study in an exploratory post
hoc analysis. The advantage of FRAX® is that it provides
estimates of 10-year fracture risk [16, 17], presenting the
opportunity to identify patients at the same level of risk at the
beginning of a 5-year observation period, as the 10-year
population at year 5, reducing confounders such as aging of
the population, prevalent fracture, and other risk factors. We
used FRAX® scores calculated without BMD in patients
already treated with strontium ranelate for 5 years, precluding
any potential bias related to the effect of treatment on BMD.
On the other hand, FRAX® does not account for the number
and severity of prevalent fractures, which is a limitation of the
tool. Our results of lower rates of fracture in the patients
between 5 and 10 years of treatment versus this matched
placebo group strongly support sustained long-term antifrac-
ture efficacy of strontium ranelate over 10 years.
Our observation of a similar efficacy between 6 and
10 years as in the first 5 years of treatment is also in line
with the reported absence of influence of age, baseline
BMD, or other risk factors on the efficacy of strontium
ranelate [11]. Moreover, a recent analysis by Kanis
confirmed that the efficacy of strontium ranelate in clinical
and morphometric fracture did not depend on baseline
fracture risk assessed by FRAX® [20], whereas the same
analyses performed with antiresorptive agents such as
denosumab [21] and clodronate [22] indicated efficacy
against clinical osteoporotic fracture in patients at moderate
and/or high risk only. The levels of compliance with
strontium ranelate over 10 years compare well with those
reported in the long-term studies with alendronate [2, 23],
even considering the design of this extension study, in
which the patients themselves chose to continue treatment.
Our study has the limitations ofmany long-term trials in the
management of a chronic disease (absence of comparator,
small sample size, and open-label design). The absence of
placebo group in the second 5-year period precluded any
direct demonstration of antifracture efficacy, and so only
indirect comparisons were possible. Participation in the
extension was based on the patients’ decision, which could
have resulted in selection bias. The aging of the population
may also have had an impact, with elderly patients being less
likely to continue. On the other hand, baseline characteristics
showed that the 10-year population was representative of the
original populations. One limitation of the comparison with
the FRAX®-matched placebo may be that the patients in the
10-year population were treated prior to entry into the
extension phase. Another limitation is that the fracture
incidences in the FRAX®-matched placebo group are
peripheral fracture, whereas FRAX® predicts the 10-year
probability of major osteoporotic fracture, defined as clinical
spine, forearm, humerus, or hip fracture. In this context, the
incidence of major osteoporotic fracture in the 10-year
population was 16.0±2.4% during the 5-year extension study,
which should be compared with the 10-year probability of
25.8±9.6% given by FRAX® and the incidence of major
osteoporotic fracture in the TROPOS placebo group over
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5 years, which was 21.2±2.1%. Clearly, a long-term placebo-
controlled trial would be the best source of information on the
benefits of long-term treatment. However, once efficacy has
been demonstrated in relatively short-term trials, it is not
possible to conduct long-term, placebo-controlled trials for
ethical reasons, particularly in studies including patients at
high risk of fracture. A new method for simulating the long-
term effects of treatment using data from placebo-controlled
trials with extensions was recently proposed by Vittinghoff
[24] and applied retrospectively to long-term data for
alendronate with limited results. This is not a commonly
used method that has also several limitations, in that it
requires substantial assumptions and does not entirely
control for potential selection and secular effects.
In conclusion, the management of patients with post-
menopausal osteoporosis should include a treatment with
both sustained antifracture efficacy in the long-term and a
safe long-term profile. Long-term treatment with strontium
ranelate is associated with sustained increases in BMD over
10 years, with a good tolerance. Our results also support the
maintenance of antifracture efficacy over 10 years with
strontium ranelate.
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